The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Key Takeaways Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

Pfizer Inc. abruptly ended a key hemophilia A gene therapy collaboration with Sangamo Therapeutics Inc., sending the East Bay biotech company's stock sharply lower as its partnership options thinned.